- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02249143
Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants
August 26, 2019 updated by: Cynthia McEvoy, Oregon Health and Science University
The primary aim of this study is to quantify and compare changes in lung volumes (as measured by functional residual capacity) in premature infants stable on continuous positive airway pressure (CPAP), and then randomized to two additional weeks of CPAP and room air versus room air alone.
We hypothesize that infants randomized to additional CPAP will demonstrate an increased functional residual capacity (at the end of the two week study period and prior to discharge) compared to those randomized to room air.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 1 year (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Gestational age at birth <33 weeks
- Required CPAP for a minimum of 24 hours for respiratory distress
- Patient on CPAP and room air at time of randomization
Exclusion Criteria:
- Complex congenital heart disease other than patent ductus arteriosus or atrial septal defect
- Major malformations or chromosomal anomalies
- Multiple gestation greater than twins
- Culture proven sepsis or unstable at time of randomization
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: CPAP and room air
Stable premature infants on CPAP and room air will be randomized to stay on CPAP for an additional two weeks.
|
Stable premature infants on CPAP and room air and meeting specific stability criteria will be randomized to stay on continuous positive airway pressure and room air for an additional two weeks or will be transitioned to room air alone.
Other Names:
|
No Intervention: Room air
Premature stable infants on CPAP and room air will be randomized to transition to room air alone.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the Measurements of Functional Residual Capacity (FRC) in Randomized Premature Infants
Time Frame: Just prior to randomization, two weeks later and at discharge (an average of 34 to 37 weeks of corrected gestational age).
|
Functional residual capacity (FRC) was measured with the nitrogen washout technique.
For the nitrogen washout technique, calibration is done with 2 known volumes, and a calibration line was constructed for the system at the specific flow rate and used to correlate the nitrogen washed out to the infant's FRC.
The system corrected for dead space and corrected the FRC to body temperature, pressure, and water-saturated conditions.
Acceptance criteria included: 1) infant supine and quietly asleep; 2) test initiated at end expiration; 3) no evidence of leak on tracing of the washout; 4) consistent tracings; 5) at least 2-3 measurements with a coefficient of variation <10%.
These are testing and acceptance criteria outlined by the American Thoracic Society and European Respiratory Society.
|
Just prior to randomization, two weeks later and at discharge (an average of 34 to 37 weeks of corrected gestational age).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurements of Passive Respiratory Compliance in Randomized Premature Infants
Time Frame: Just before randomization, two weeks later, and at discharge at about 35-37 weeks of corrected gestational age
|
Measurements of passive respiratory compliance will be done with the single breath occlusion technique.
|
Just before randomization, two weeks later, and at discharge at about 35-37 weeks of corrected gestational age
|
Passive Respiratory Resistance in Randomized Premature Infants
Time Frame: Just prior to randomization, two weeks after randomization, and at discharge at about 35-37 weeks of corrected gestational age.
|
Measurements of passive respiratory resistance will be done with the single breath occlusion technique.
|
Just prior to randomization, two weeks after randomization, and at discharge at about 35-37 weeks of corrected gestational age.
|
Measurements of Tidal Flow Volume Loops Will be Done in the Randomized Premature Infants.
Time Frame: Just before randomization, two weeks later, and at discharge at about 35-37 weeks of corrected gestational age.
|
Characteristics of tidal flow volume loops will be measured.
|
Just before randomization, two weeks later, and at discharge at about 35-37 weeks of corrected gestational age.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the Growth Parameters Between the Randomized Premature Infants
Time Frame: From randomization through discharge at about 35-37 weeks of corrected gestational age.
|
Changes in growth parameters will be compared between randomized groups.
|
From randomization through discharge at about 35-37 weeks of corrected gestational age.
|
The Number of Participants With Adverse Events and Serious Adverse Events in the Randomized Groups of Premature Infants.
Time Frame: From randomization through discharge from the neonatal intensive care unit (an average of 35 to 37 weeks of corrected gestational age).
|
Adverse events and serious adverse events occurring in the randomized groups will be documented carefully
|
From randomization through discharge from the neonatal intensive care unit (an average of 35 to 37 weeks of corrected gestational age).
|
Corrected Gestational Age at Which Full Nipple Feeds Are Achieved
Time Frame: Randomization through discharge at about 35-37 weeks of corrected gestational age.
|
The corrected gestational age at which full nipple feeds are achieved will be compared between the randomized groups.
|
Randomization through discharge at about 35-37 weeks of corrected gestational age.
|
Incidence of Wheezing Through One Year of Age
Time Frame: Discharge through one year of corrected age
|
Incidence of wheezing will be compared through one year of corrected gestational age between the randomized groups.
|
Discharge through one year of corrected age
|
Cost Comparison Between Randomized Groups
Time Frame: Through 12 months of corrected age
|
Cost comparison through 12 months of corrected gestational age between the randomized groups per percent improvement in FRC measured at discharge between the groups.
|
Through 12 months of corrected age
|
Days on Oxygen Between the Randomized Groups
Time Frame: Through discharge at about 35-37 weeks of corrected gestational age
|
The days of oxygen supplementation will be compared between the groups of randomized patients.
|
Through discharge at about 35-37 weeks of corrected gestational age
|
Days in the Hospital
Time Frame: Delivery through discharge at about 35-37 weeks of corrected gestational age
|
The days in the hospital will be compared between the randomized groups.
|
Delivery through discharge at about 35-37 weeks of corrected gestational age
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Cindy T McEvoy, MD, MCR, Oregon Health and Science University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2014
Primary Completion (Actual)
May 1, 2016
Study Completion (Actual)
September 1, 2017
Study Registration Dates
First Submitted
August 28, 2014
First Submitted That Met QC Criteria
September 22, 2014
First Posted (Estimate)
September 25, 2014
Study Record Updates
Last Update Posted (Actual)
August 29, 2019
Last Update Submitted That Met QC Criteria
August 26, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- eIRB00010607
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Distress Syndrome
-
Tanta UniversityRecruitingAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | Respiratory Distress Syndrome, PediatricEgypt
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Dr Anna Lavizzari; Dr Francesca Gaia CiuffiniCompletedNewborn Respiratory Distress SyndromeItaly
-
University Hospital, Clermont-FerrandWithdrawn
-
Assiut UniversityRecruitingNeonatal Respiratory DistressEgypt
-
Groupe Hospitalier Paris Saint JosephCompletedEarly Neonatal Respiratory Distress: Changes in Level IIb Hospital Over a Period of One Year (DROPE)Neonatal Respiratory Distress SyndromeFrance
-
Karolinska University HospitalCompletedRespiratory Distress Syndrome, Adult | Respiratory Distress Syndrome, ChildSweden
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAcute Respiratory Distress Syndrome ARDS
-
Michael A. MatthayThe University of Texas Health Science Center, Houston; United States Department... and other collaboratorsCompletedRespiratory Distress Syndrome, AdultUnited States
-
Faron Pharmaceuticals LtdSeventh Framework ProgrammeTerminatedRespiratory Distress Syndrome, AdultSpain, United Kingdom, France, Italy, Finland, Czechia, Belgium, Germany
-
Postgraduate Institute of Medical Education and...TerminatedAcute Respiratory Distress Syndrome (ARDS)India
Clinical Trials on CPAP and room air
-
Johns Hopkins UniversityNational Institutes of Health (NIH)Completed
-
Spaulding Rehabilitation HospitalFoundation Wings For LifeActive, not recruitingSpinal Cord InjuriesUnited States
-
Emory UniversityUniversity of Wisconsin, Madison; University of SaskatchewanCompletedSpinal Cord InjuryUnited States
-
Loma Linda UniversityWithdrawnIntracranial Hemorrhages | Respiratory Distress Syndrome, Newborn | Hypoxic-Ischemic Encephalopathy | Perinatal Death | Neonatal Seizure | Meconium Aspiration Syndrome | Neonatal HypotensionUnited States
-
Emory UniversityNorthwestern University; University of Wisconsin, Madison; University of Saskatchewan and other collaboratorsCompletedSpinal Cord InjuryUnited States
-
Duke UniversityNot yet recruitingPulmonary HypertensionUnited States
-
Region SkaneCompletedST Elevation Myocardial InfarctionSweden
-
Massachusetts General HospitalCompleted
-
University of British ColumbiaCompletedLung; Disease, Interstitial, With FibrosisCanada
-
University of ZurichCompletedChronic Obstructive Pulmonary Disease (COPD)Switzerland